We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

SD BIOSENSOR

SD BIOSENSOR develops immunological and molecular diagnostics and blood glucose self-monitoring systems, glycated hem... read more Featured Products: More products

Download Mobile App




Rapid Tests Evaluated in the Management of Dengue Fever

By LabMedica International staff writers
Posted on 12 Nov 2020
Dengue is a mosquito-borne infection caused by four distinct viruses (DENV 1-4) which belong to the flavivirus genus and may lead to diverse outcomes. More...
The disease can be asymptomatic in about 75% of cases, causing Dengue fever (DF), or result in severe dengue. Dengue is common in more than 120 countries.

The laboratory diagnosis, essential to recognize dengue cases, is based on viral isolation, serological tests, and detection of viral RNA. Isolation is cumbersome, requires high biocontainment and often takes too long for clinical management. The use of rapid diagnostic tests (RDTs) may be of help as a preliminary user-friendly quick assay to facilitate dengue diagnosis.

Infectious Disease specialists at the Lazzaro Spallanzani National Institute for Infectious Diseases (Rome, Italy) retrospectively reviewed patients with dengue-like symptoms who spontaneously sought treatment in healthcare units of Lazio Region (Central Italy) from January 2014 through July 2019. DF diagnosis was confirmed at the Regional Reference Laboratory in 102 out of 804 (12.7%) febrile patients tested. RDTs have been performed on samples derived from 651 individuals, representing the 80.9% of possible cases tested at the Institute.

A colorimetric test detecting the NS1 viral antigen and anti-DENV IgM and IgG (SD Bioline Dengue Duo, Abbott Diagnostics, Abbott Park, IL, USA) was used as preliminary assay between January 2014 and December 2017. From August 2018, the colorimetric test was replaced by fluorimetric RDTs: STANDARD F Dengue NS1 Ag FIA + STANDARD F Dengue IgM/IgG FIA (SD Biosensor, Gyeonggi-do, Republic of Korea).

Two molecular assays to detect DENV RNA were used: a real time RT-PCR (DENV-1-4 Real-Time RT-PCR Multiplex Assay, developed in 2019 by Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA), and a modified Pan-flavivirus specific nested PCR targeting NS5 region. In addition, multiple indirect immunofluorescence assays (IFA, Flavivirus Mosaic 2 or Arboviral Fever Mosaic-2, IgM and IgG (Euroimmun, Lübeck, Germany) were performed for specific IgM and IgG titers measurement and differential diagnosis.

The investigators reported that the combined use of NS1 and IgM/IgG RDT for the detection of acute dengue cases resulted in an overall sensitivity and specificity of 87.2% and 97.9% for Colorimetric RDT, and 96.2% and 96.2% for Fluorimetric RDT. NS1 was the most reliable marker of acute infection, while IgM resulted falsely positive in nine samples, including sera derived from two Zika and four non-arbovirus infected patients.

The authors concluded that although confirmatory tests are still necessary, their experience strongly supported the use of combined NS1 and IgM/IgG rapid dengue tests as first line tools for prompt case identification. The use of these tests aids the clinical management, surveillance activities, and vector control strategies. The study was published on October 1, 2020 in the International Journal of Infectious Diseases.

Related Links:
Lazzaro Spallanzani National Institute for Infectious Diseases
Abbott Diagnostics
SD Biosensor
Centers for Disease Control and Prevention
Euroimmun




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.